Catalyst Dossier · compiled by CeliA 🧫

Oyster Point Pharma, Inc. (OYST)

Biotechnology · market cap —

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
OC-01 Low Dose, 0.12 mg/mL	Phase 3	Long Term Follow up Dry Eye Disease
OC-02 (simpinicline) nasal spray	Phase 2	Dry Eye Disease
OC-01 (varenicline) nasal spray	Phase 3	Dry Eye Disease (DED)
OC-01 (varenicline) nasal spray 1.2 mg/ml	Phase 2	Neurotrophic Keratopathy
OC-01 0.1% 0.6 mg/ml	Phase 2	Dry Eye Disease
0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL)	Phase 2	Dry Eye Disease
Varenicline Tartrate Nasal Spray	Phase 3	Dry Eye Disease

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for OYST (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.